Torronteras R, Sánchez-Quijano A, Abad M A, Soto B, Andreu J, Medrano F J, Leal M, Lissen E
Department of Microbiology, Virgen del Rocio University Hospital, Seville, Spain.
J Viral Hepat. 1994;1(2):159-61. doi: 10.1111/j.1365-2893.1994.tb00116.x.
To determine the predictive value of IgM anti-hepatitis C virus (HCV) testing in patients with chronic hepatitis C infections undergoing interferon-alpha (IFN-alpha) therapy, IgM anti-HCV reactivity was analysed by two different methods (non-commercial and commercial) in 19 patients and monitored at times 0 (pretreatment), 3, 6, 12, and 24 months during follow-up. Eight patients were non-responders, five remained in sustained response 1 year after stopping treatment, and six had a relapse. No correlation between alanine transaminase (ALT) levels and IgM anti-HCV reactivity was found by either method in baseline samples. In addition, neither the presence nor absence of IgM anti-HCV in baseline samples, nor the loss of specific IgM reactivity during treatment, had any predictive value. Finally, no other parameters analysed (age, sex, risk group and histological diagnosis), were significantly associated with IgM anti-HCV reactivity in our study. In summary, these results suggest that baseline detection and monitoring of IgM anti-HCV reactivity are not useful in predicting the sustained response to IFN-alpha therapy in chronic hepatitis C infection.
为了确定丙型肝炎病毒（HCV）IgM检测在接受α干扰素（IFN-α）治疗的慢性丙型肝炎感染患者中的预测价值，采用两种不同方法（非商业方法和商业方法）对19例患者的HCV IgM反应性进行分析，并在随访期间的0（治疗前）、3、6、12和24个月进行监测。8例患者无反应，5例在停止治疗1年后持续缓解，6例复发。两种方法在基线样本中均未发现丙氨酸转氨酶（ALT）水平与HCV IgM反应性之间存在相关性。此外，基线样本中HCV IgM的存在与否，以及治疗期间特异性IgM反应性的丧失，均无任何预测价值。最后，在我们的研究中，分析的其他参数（年龄、性别、风险组和组织学诊断）与HCV IgM反应性均无显著相关性。总之，这些结果表明，HCV IgM反应性的基线检测和监测对预测慢性丙型肝炎感染患者对IFN-α治疗的持续反应并无帮助。
